Comparing Antipsychotic Medications in LBD Over Time

• Status: Recruiting
• Trial end date: 2025-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center at San Antonio
• Collaborator: Alzheimer's Association
• Treatments: Pimavanserin; Quetiapine Fumarate

Criteria

Inclusion Criteria:

• Patients seen in the neurology clinic at UT Health San Antonio

• Diagnosed with psychosis due to PD or DLB

• Requiring initiation of an antipsychotic medication

• Clinical equipoise between quetiapine and pimavanserin must exist

• The prescribing provider must be comfortable prescribing and managing both quetiapine and pimavanserin

Exclusion Criteria:

• Medical contraindication to either medication

• Caregiver unavailable to complete NPI-Q

• Currently taking an antipsychotic medication

• Prescribing provider unwilling to manage either medication